Skip to main content
Addex Therapeutics Ltd. logo

Addex Therapeutics Ltd. — Investor Relations & Filings

Ticker · ADXN ISIN · CH0029850754 LEI · 89450068Y9KVP2MQGH86 SW Manufacturing
Open in API
Filings indexed 338 across all filing types
Latest filing 2024-04-03 M&A Activity
Country CH Switzerland
Listing SW ADXN

About Addex Therapeutics Ltd.

http://www.addextherapeutics.com/en/

Addex Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel, orally available small molecule drugs. The company specializes in an emerging class of therapeutics known as allosteric modulators. Its development pipeline targets neurological disorders and other central nervous system (CNS) diseases with significant unmet medical needs, leveraging its proprietary drug discovery platform.

Recent filings

Filing Released Lang Actions
Addex and Perceptive Launch Neurosterix with $63 Million to Accelerate Development of Allosteric Modulator Therapeutics for Neurological Disorders
M&A Activity Classification · 99% confidence The document is titled "Ad Hoc Announcement Pursuant to Art. 53 LR" and details a significant corporate transaction: the launch of a new company (Neurosterix) involving the transfer of assets from Addex Therapeutics and securing new funding from Perceptive Advisors. It includes key financial figures (CHF5M, $63M), strategic rationale, management changes, and pipeline updates. This type of announcement, detailing a major corporate event or financing activity outside of routine periodic reporting, fits best under the Capital/Financing Update category, as it explicitly discusses funding ($63M investment) and capital structure changes (receiving cash and equity). While it involves management changes, the primary focus is the transaction itself. It is not a full 10-K, an ER (which focuses on periodic results), or a standard regulatory filing (RNS) given the specific nature of the transaction described. Therefore, 'CAP' is the most appropriate classification.
2024-04-03 English
Addex to Present at the Bio-Europe Spring 2024 Conference
Report Publication Announcement Classification · 99% confidence The document is a press release dated March 14, 2024, announcing that the CEO will present at the Bio-Europe Spring 2024 conference on March 19, 2024. It details the presentation time, location, and availability for one-on-one meetings. This type of announcement, which communicates an upcoming corporate event (like a conference presentation) where management will provide updates, aligns best with an Investor Presentation (IP) or a general announcement. Since it is not a formal financial report (like 10-K or IR), nor a transcript of a call, nor a formal dividend/share change notice, it is an announcement intended for investors regarding future engagement and corporate updates. While it is an announcement, it is specifically about management presenting information, which is closely related to an Investor Presentation (IP) or a general corporate update. Given the options, 'Investor Presentation' (IP) is the closest fit for an announcement detailing management's planned presentation of corporate updates at an industry conference, even though the presentation itself is not attached. However, because this is a short press release announcing *attendance* and a *presentation slot* rather than the presentation material itself, it functions primarily as a general corporate communication. If the document were the actual presentation slides, IP would be correct. As a short announcement about management speaking at an event, it is a general corporate update. Since there is no specific 'Conference Presentation Announcement' code, and it is not a formal regulatory filing (RNS) or a report, it is best classified as an Investor Presentation (IP) as it is directly related to investor outreach and corporate messaging, or potentially RNS as a general announcement. Given the content focuses heavily on what the CEO will discuss ('corporate update and discuss recent developments'), IP is a stronger fit than the generic RNS.
2024-03-14 English
Addex Enters into At-The-Market ADS Offering Agreement with H.C. Wainwright & Co. LLC.
Share Issue/Capital Change Classification · 99% confidence The document is an 'Ad Hoc Announcement' dated January 31, 2024, detailing an 'At The Market Offering Agreement' (ATM) with H.C. Wainwright & Co., LLC. This agreement allows the company to offer and sell up to $2.1 million in ADSs. The text explicitly mentions that the offering will be made pursuant to the company's effective registration statement on Form F-3. The core subject is a financing activity—the establishment of a mechanism to raise capital through the sale of shares/ADSs. This directly aligns with the definition of 'Capital/Financing Update' (CAP). It is not a full annual report (10-K), an earnings release (ER), or a dividend notice (DIV).
2024-01-31 English
424B5
Regulatory Filings
2024-01-30 English
FORM 6-K
Regulatory Filings
2024-01-30 English
Addex to Present at the Swiss Equities Baader Conference
Regulatory Filings Classification · 99% confidence The document is a press release dated January 9, 2024, announcing that the Head of Discovery - Biology will present at the Swiss Equities Baader Conference on January 11, 2024. It details the presentation time, venue, and availability for one-on-one meetings. This type of announcement, which publicizes a company executive's participation in an external industry conference, does not fit the definitions for formal financial reports (10-K, IR, ER, MRQ) or specific corporate actions (DIV, CAP, SHA). It is an announcement related to investor relations activities, specifically a corporate update presentation at a conference. While it is a form of investor communication, it is not a formal Investor Presentation (IP) which usually contains detailed slides/data, nor is it a Call Transcript (CT). Given the options, this is best classified as a general announcement related to investor engagement, which often falls under Regulatory Filings (RNS) if no better fit exists, or potentially a very broad interpretation of Investor Presentation (IP) if the content discussed is strategic. However, since the core purpose is announcing *attendance* and a *corporate update* at a third-party conference, and it is not a formal presentation document itself, RNS (Regulatory Filings/Miscellaneous Announcement) is the most appropriate fallback, as it is a standard press release format announcing an event.
2024-01-09 English

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.